Turn off MathJax
Article Contents
LAN Sihan. Phylogenetic Analyses of HPV53 and Prediction of B and T Cell Epitopes[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2024-0138
Citation: LAN Sihan. Phylogenetic Analyses of HPV53 and Prediction of B and T Cell Epitopes[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2024-0138

Phylogenetic Analyses of HPV53 and Prediction of B and T Cell Epitopes

doi: 10.12290/xhyxzz.2024-0138
  • Received Date: 2024-03-07
  • Accepted Date: 2024-04-17
  • Available Online: 2024-04-24
  • Objective The objective of this study was to construct phylogenetic trees based on HPV53 full length sequences, as well as to predict the physical and chemical parameters, secondary structure, B and T cell epitopes of HPV53 proteins (E1, E2, E4, E6, E7, L1, and L2). Method Full length of HPV53 variants were Obtained from the GenBank and a phylogenetic tree was constructed to define variant lineages. The physical and chemical parameters of HPV53 proteins were analyzed by ProtParam. The secondary structure of proteins was analyzed using PSIPRED and SOPMA. The B and T cell epitopes for HPV53 proteins were predicted by the IEDB analysis server and the ABCpred server, respectively. Then, to select the potential dominant B and T cell epitopes, more parameters including flexibility, hydrophilicity, surface accessibility, antigenicity of predicted B and T cell epitopes were further predicted by bioinformatic methods (e.g., DNASTAR-Protean, VaxiJen, etc.). Finally, for homology analysis, the potential dominant B and T cell epitopes were compared with the 13 high-risk HPV subtypes using NCBI BLAST tool. Results Phylogenetic analyses clustered HPV53 variants into 3 lineages designated A, B, and C. The physicochemical properties of three different HPV53 variants (representing A, B, and C lineages, respectively) were similar, while slight differences in secondary structure were observed. There were 6 potential dominant B cell epitopes and 9 potential dominant T cell epitopes were predicted for HPV53 proteins. Among these epitopes, B cell epitopes TTPIRPPPPPRPWAPT in E4 region and CYRCQHPLTPEEKQLH in E6 region, and T cell epitopes SGVHSYEEIPMQ in L2 region showed high homologous to HPV56 (all>90%). Conclusions Using bioinformatic tools, B and T cell epitopes for all proteins of HPV53 were predicted, which provides the basis for further research on epitope vaccines against HPV53.
  • loading
  • [1] MCBRIDE A A. Human papillomaviruses:diversity, infection and host interactions[J]. Nat Rev Microbiol, 2022, 20(2):95-108.
    [2] 中华医学会妇科肿瘤学分会,中国优生科学协会阴道镜和宫颈病理学分会.人乳头瘤病毒疫苗临床应用中国专家共识[J].协和医学杂志, 2021, 12:13.
    [3] EBERHARDT C S, KISSICK H T, PATEL M R, et al. Functional HPV-specific PD-1(+) stem-like CD8 T cells in head and neck cancer[J]. Nature, 2021, 597(7875):279-84.
    [4] MANGA S M, YE Y, NULAH K L, et al. Human Papillomavirus Types and Cervical Cancer Screening among Female Sex Workers in Cameroon[J]. Cancers (Basel), 2024, 16(2).
    [5] CHEN L, DONG Y, LI J, et al. The genomic distribution map of human papillomavirus in Western China[J]. Epidemiol Infect, 2021, 149:e135.
    [6] ZENG Z, AUSTIN R M, WANG L, et al. Nationwide Prevalence and Genotype Distribution of HighRisk Human Papillomavirus Infection in China[J]. Am J Clin Pathol, 2022, 157(5):718-23.
    [7] ZHANG J, CHENG K, WANG Z. Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China:a meta-analysis[J]. Arch Gynecol Obstet, 2020, 302(6):1329-37.
    [8] LIU L, WANG D, DONG H, et al. Characteristics of carcinogenic HPV genotypes in North China Plain and the association with cervical lesions[J]. Medicine (Baltimore), 2019, 98(37):e17087.
    [9] MA M, ZHU J, YANG Y, et al. The distribution and pathogenic risk of non-9-valent vaccine covered HPV subtypes in cervical lesions[J]. Cancer Med, 2022, 11(6):1542-52.
    [10] HARDEN M E, MUNGER K. Human papillomavirus molecular biology[J]. Mutat Res Rev Mutat Res, 2017, 772:3-12.
    [11] DELLA FERA A N, WARBURTON A, COURSEY T L, et al. Persistent Human Papillomavirus Infection[J]. Viruses, 2021, 13(2).
    [12] MCBRIDE A A. Mechanisms and strategies of papillomavirus replication[J]. Biol Chem, 2017, 398(8):919-27.
    [13] BERNARD H U. Regulatory elements in the viral genome[J]. Virology, 2013, 445(1-2):197-204.
    [14] LETUNIC I, BORK P. Interactive Tree Of Life (iTOL) v5:an online tool for phylogenetic tree display and annotation[J]. Nucleic Acids Research, 2021, 49(W1):W293-W6.
    [15] 吴玉章,朱锡华.一种病毒蛋白B细胞表位预测方法的建立[J].科学通报, 1994,(24):2275-9.
    [16] HE J, YANG Y, CHEN Z, et al. Identification of variants and therapeutic epitopes in HPV-33/HPV-58 E6 and E7 in Southwest China[J]. Virol J, 2019, 16(1):72.
    [17] BURK R D, HARARI A, CHEN Z. Human papillomavirus genome variants[J]. Virology, 2013, 445(1-2):232-43.
    [18] CHEN Z, SCHIFFMAN M, HERRERO R, et al. Evolution and taxonomic classification of human papillomavirus 16(HPV16)-related variant genomes:HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67[J]. PLoS One, 2011, 6(5):e20183.
    [19] SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-49.
    [20] Estimated numbers (incidence and mortality) of cancer of cervix uteri from 2020 to 2040, females, age[0-85+], China[Z]. https://gco.iarc.fr/tomorrow/en/dataviz/trends?sexes=2&cancers=23&populations=160; International Agency for Research on Cancer (IARC). 2023
    [21] CAO M, CHENZHANG Y, DING X, et al. Genetic variability and lineage phylogeny of human papillomavirus type-16 and-53 based on the E6, E7, and L1 genes in Southwest China[J]. Gene, 2016, 592(1):49-59.
    [22] MARIZ F C, PUTZKER K, SEHR P, et al. Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2[J]. Front Immunol, 2023, 14:1272018.
    [23] OLCZAK P, RODEN R B S. Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated Diseases[J]. Vaccines (Basel), 2020, 8(4).
    [24] KADAJA M, ISOK-PAAS H, LAOS T, et al. Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses[J]. PLoS Pathog, 2009, 5(4):e1000397.
    [25] DOORBAR J. The E4 protein; structure, function and patterns of expression[J]. Virology, 2013, 445(1-2):80-98.
    [26] BRAVO I G, ALONSO A. Mucosal human papillomaviruses encode four different E5 proteins whose chemistry and phylogeny correlate with malignant or benign growth[J]. J Virol, 2004, 78(24):13613-26.
    [27] SCHIFFMAN M, HERRERO R, DESALLE R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution[J]. Virology, 2005, 337(1):76-84.
    [28] MCINNIS C, BHATIA S, VIJAYKUMAR B, et al. Identification of HPV16 E1 and E2-specific T cells in the oropharyngeal cancer tumor microenvironment[J]. J Immunother Cancer, 2023, 11(3).
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (18) PDF downloads(2) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return